登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>TGF-beta 1 >TG1-H4212

Human TGF-Beta 1 / TGFB1 Protein, Tag Free

分子别名(Synonym)

CEDLAP,TGF-beta 1,TGFB1,DPD1,TGF-beta-1,TGFB

表达区间及表达系统(Source)

Human TGF-Beta 1 Protein, Tag Free (TG1-H4212) is expressed from human 293 cells (HEK293). It contains AA Ala 279 - Ser 390 (Accession # P01137-1).

Predicted N-terminus: Ala 279

Request for sequence

蛋白结构(Molecular Characterization)

TGF-beta 1 Structure

This protein carries no "tag".

The protein has a calculated MW of 12.8 kDa (monomer). The protein migrates as 14 kDa (monomer) under reducing (R) condition, and 25 kDa (Dimer) when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE).

内毒素(Endotoxin)

Less than 0.1 EU per μg by the LAL method.

宿主蛋白残留(Host Cell Protein)

<0.5 ng/µg of protein tested by ELISA.

宿主核酸残留(Host Cell DNA)

<0.02 ng/μg of protein tested by qPCR.

无菌(Sterility)

Negative

支原体(Mycoplasma)

Negative.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in 0.085% TFA in 30% ACN with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 12 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

TGF-beta 1 SDS-PAGE

Human TGF-Beta 1 Protein, Tag Free on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

 

活性(Bioactivity)-ELISA

TGF-beta 1 ELISA

Immobilized Human TGF-Beta 1 Protein, Tag Free (Cat. No. TG1-H4212) at 0.2 μg/mL (100 μL/well) can bind Human TGFBR2, Fc Tag (Cat. No. TG2-H5252) with a linear range of 0.2-2.5 ng/mL (QC tested).

Protocol

 

活性(Bioactivity)-SPR

TGF-beta 1 SPR

Human TGF-Beta 1 Protein, Tag Free (Cat. No. TG1-H4212) immobilized on CM5 Chip can bind Human TGF-beta RI Protein, Fc Tag (Cat. No. TG1-H5254) with an affinity constant of 99.2 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

 

活性(Bioactivity)-CELL BASE

TGF-beta 1 CELL

Human TGF-Beta 1 Protein, Tag Free (Cat. No. TG1-H4212) inhibits the Human IL-4, premium grade (Cat. No. IL4-H4218) dependent proliferation the TF-1 cells. The specific activity of Human TGF-Beta 1 Protein, Tag Free is > 8.00ⅹ10^6 IU/mg, which is calibrated against transforming growth factor β1 (NIBSC code: 89/514) (QC tested).

Protocol

 
 
ACRO质量管理体系
 
 

背景(Background)

Transforming growth factor beta 1 ( TGFB1) is also known as TGF-β1, CED, DPD1, TGFB. is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis. The TGFB1 protein helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement (motility), and the self-destruction of cells (apoptosis). The TGFB1 protein is found throughout the body and plays a role in development before birth, the formation of blood vessels, the regulation of muscle tissue and body fat development, wound healing, and immune system function. TGFB1 is particularly abundant in tissues that make up the skeleton, where it helps regulate bone growth, and in the intricate lattice that forms in the spaces between cells (the extracellular matrix). Within cells, this protein is turned off (inactive) until it receives a chemical signal to become active. TGFB1 plays an important role in controlling the immune system, and shows different activities on different types of cell, or cells at different developmental stages. Most immune cells (or leukocytes) secrete TGFB1. TGFB1 has been shown to interact with TGF beta receptor 1, LTBP1, YWHAE, EIF3I and Decorin.

文献引用(Citations)

 

前沿进展

Targeting novel immune checkpoints in the B7-H family: advancing cancer immunotherapy from bench to bedside
Luo, Yuan, Liu et al
Trends Cancer (2025)
Abstract: The B7-H family of immune checkpoint molecules is a crucial component of the immune regulatory network for tumors, offering new opportunities to modulate the tumor microenvironment (TME). The B7-H family - which includes B7-H2 (inducible T cell costimulatory ligand, ICOSL), B7-H3, B7-H4, B7-H5 (V-domain immunoglobulin suppressor of T cell activation, VISTA), B7-H6, and B7-H7 (HHLA2) - is known for its diverse roles in regulating innate and adaptive immunity. These molecules can exhibit co-stimulatory or co-inhibitory effects on T cells, influencing processes such as T cell activation, differentiation, and effector functions, and they are involved in the recruitment and polarization of various immune cells. This review explores the structural characteristics, receptor-ligand interactions, and signaling pathways associated with each B7-H family member. We also discuss the family's impact on tumor immunity and potential therapeutic strategies.Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Development of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review
Yamanaka, Nishikawa, Yoshida
Cells (2025) 14 (5)
Abstract: Despite recent advances in cancer treatment, the prognosis for uterine malignancies (carcinoma and sarcoma) requires further improvement. Antibody-drug conjugates (ADCs) have emerged as a novel class of anti-cancer therapeutic agents, and multiple ADCs have been approved for other types of cancer. In 2024, trastuzumab deruxtecan received approval from the US Food and Drug Administration for cancer types and became the first ADC approved for the treatment of uterine malignancies. Many ADCs are currently being investigated in uterine malignancies, and therefore, there is a need to gain a deeper understanding of ADCs. In this article, we aim to provide a comprehensive overview of the advancements in ADCs. The contents of this article include the structure and mechanism of action, an analysis of recent clinical trials, and expected future clinical questions. This article also focuses on uterine sarcoma, which is not often highlighted as a target for ADC treatment.
A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective
Zhao, Yuan, Li et al
Int J Biol Macromol (2025) 304 (Pt 2), 140767
Abstract: Ovarian cancer is one of the most lethal gynaecologic cancers in China. Although platinum-based chemotherapy, PARP inhibitors and bevacizumab have prolonged long term survival and increased the overall response rate for platinum-sensitive ovarian cancer (PSOC), the treatment options for platinum-resistant ovarian cancer (PROC) are still limited. Antibody-drug conjugates (ADCs) represent a novel form of precision medicine, covalently linking specific monoclonal antibodies with potent cytotoxic payloads. Since mirvetuximab soravtansine (MIRV) received approval by the US Food and Drug Administration (FDA) as the first ADC for PROC in 2022, the development of novel ADCs for various targets in PROC has accelerated. In this review, we summarise the recent evidence and future prospects of ADCs targeting Folate Receptor alpha (FRα), mesothelin, cadherin-6, NaPi2b, human epidermal growth factor receptor 2 (HER2), dipeptidase 3 (DPEP3), B7-H4 (VTCN1), claudin-6 (CLDN6) and trophoblast antigen protein 2 (TROP2), in order to enhance our understanding of the clinical applications of ADCs and offer new insights for clinical practice and further research.Copyright © 2025. Published by Elsevier B.V.
Exploring B7-H4's role in prostate cancer dormancy post-androgen deprivation therapy: extracellular matrix interactions and therapeutic opportunities
Kang, Xue, Wong et al
Mol Cancer Res (2025)
Abstract: Prostate cancer (PCa) is mainly managed with androgen deprivation therapy (ADT), but this often leads to a dormant state and subsequent relapse as lethal castration-resistant prostate cancer (CRPC). Using our unique PCa patient-derived xenograft (PDX) dormancy models, we investigated this critical dormant phase and discovered a selective increase in B7-H4 expression during the dormancy period following mouse host castration. This finding is supported by observations in clinical specimens of PCa patients treated with ADT. Differential expression analyses revealed the enrichment of extracellular matrix (ECM)-cell interaction pathways in B7-H4-positive cells. Functional assays demonstrated a crucial role of B7-H4 in maintaining dormancy within the ECM niche. Specifically, B7-H4 expression in LNCaP cells reduced proliferation within dormant ECM in vitro and significantly delayed relapse in castrated hosts in vivo. These results shed light on the dynamic regulation of B7-H4 during PCa dormancy and underscore its potential as a therapeutic target for preventing CRPC relapse. Implications: Our study identified membranous B7-H4 expression during ADT-induced dormancy, highlighting its potential as a therapeutic target for managing dormant prostate cancer and preventing fatal CRPC relapse.
Showing 1-4 of 505 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
TGF-beta 1靶点信息
英文全称:Transforming growth factor beta 1
中文全称:转化生长因子β1
种类:Homo sapiens
上市药物数量:1详情
临床药物数量:21详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定